| [1] |
Sun J, Li M, Fan S, et al.A novel liver-targeted nitric oxide donor UDCA-Thr-NO protects against cirrhosis and portal hypertension [J]. Am J Transl Res, 2018, 10(2): 392-340.
|
| [2] |
Wereszczynka-Siemiatkowska U, Swidnicka-Siergiejko A, Siemiatkowski A, et al.Endothelin 1 and transforming growth factor-β1 correlate with liver function and portal pressure in cirrhotic patients [J]. Cytokine, 2015, 76(2): 144-151.
|
| [3] |
Chen Y, Wang CP, Lu YY, et al.Hepatic stellate cells may be potential effectors of platelet activating factor induced portal hypertension [J]. World J Gastroenterol, 2008, 14(2): 218-223.
|
| [4] |
任晓丽，时永全，韩英．血管生物学在门静脉高压症治疗中的作用[J]．临床肝胆病杂志，2015，31(3): 478-480.
|
| [5] |
庞书杰，叶庆旺，施洋，等．门静脉高压性胆病临床诊疗进展[J]．肝胆胰外科杂志，2015，27(5): 431-433.
|
| [6] |
Le Roy B, Gelli M, Serji B, et al.Portal biliopathy as a complication of extrahepatic portal hypertension: etiology, presentation and management [J]. J Visc Surg, 2015, 152(3): 161-166.
|
| [7] |
陈平，吴云林．食管静脉曲张内镜下治疗对门静脉高压性胃病的影响机制研究[J]．诊断学理论与实践，2016，15(5): 349-352.
|
| [8] |
Bang CS, Kim HS, Suk KT, et al.Portal hypertensive gastropathy as a prognostic index in patients with liver cirrhosis [J]. BMC Gastroenterol, 2016, 16(1): 93.
|
| [9] |
邱隆敏，李佳，杨福秀，等．肝硬化患者血浆胃泌素、胃动素与门静脉高压的关系[J]．临床荟萃，2005，20(18): 1047-1048.
|
| [10] |
谷雷雷，朱时燕，忻笑容，等．门静脉高压性胃病急性出血的临床诊断[J]．诊断学理论与实践，2016，15(05): 459-463.
|
| [11] |
尹朝晖，刘浔阳．门静脉高压性肠病[J]．世界华人消化杂志，2003，11(10): 1569-1571.
|
| [12] |
Mekaroonkamol P, Cohen R, Chawla S. Portal hypertensive enteropathy [J]. World J Hepatol, 2015, 7(2): 127-138.
|
| [13] |
彭涛，刘玉兰．门静脉高压症导致的异位静脉曲张[J]．胃肠病学和肝病学杂志，2007，16(1): 15-17.
|
| [14] |
张梦茵，朱燕华，吴云林．门静脉高压胃静脉曲张分型及治疗进展[J]．内科理论与实践，2014，9(2): 163-165.
|
| [15] |
邵娜，杨宇，马芮，等．肝性脊髓病[J]．中风和神经病杂志，2017，34(11): 1054-1056 .
|
| [16] |
Wani ZA, Mohapatra S, Khan AA, et al.Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension [J]. World J Hepatol, 2017, 9(5): 270-277.
|
| [17] |
Moctezuma-Velázquez C, Abraldes JG, Montano-Loza AJ.The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis [J]. Curr Treat Options Gastroenterol, 2018, 16(2): 226-240.
|
| [18] |
Cheng TY, Lee WS, Huang HC, et al.The effects of pioglitazone in cirrhotic rats with hepatopulmonary syndrome [J]. J Chin Med Assoc, 2017, 80(11): 683-689.
|
| [19] |
夏橞生．肝硬化门静脉高压症时不宜盲目实施脾切除术[J]．中华肝胆外科杂志，2006，12(9): 583-585.
|
| [20] |
付焱，张超．覆膜支架与裸支架TIPS比较治疗门静脉高压疗效的Meta分析[J]．中国循证医学杂志，2018，18(1): 35-42.
|
| [21] |
Park JK, Saab S, Kee ST, et al.Balloon-Occluded Retrograde Transvenous Obliteration(BRTO)for Treatment of Gastric Varices: Review and Meta-Analysis [J]. Dig Dis Sci, 2015, 60(6): 1543-1553.
|
| [22] |
Miyamoto Y, Oho K, Kumamoto M, et al.Balloon-occluded retrograde transvenous obliteration improves liver function in pat ients with cirrhosis and portal hypertension [J]. J Gastroenterol Hepatol, 2003, 18(8): 934-942.
|
| [23] |
彭伦华，王运兵，郭灿．球囊阻断逆行经静脉闭塞对比经颈静脉肝内门体分流治疗门静脉高压胃底静脉曲张出血的Meta分析[J]．介入放射学杂志，2016，25(10): 843-848.
|